Skip to main content
. 2016 Sep 28;10:3153–3161. doi: 10.2147/DDDT.S115493

Figure 4.

Figure 4

Relative risk of all-grade elevated ALT (A) and AST (B) and high-grade elevated ALT (C) and AST (D) for cancer patients receiving a nivolumab/ipilimumab combination compared with ipilimumab control.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; PD-1, program death 1; CI, confidence interval.